Huons Meditech showcases innovations at conferences in New Delhi and Jakarta

2024. 10. 30. 00:00
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

Huons Meditech, under the leadership of CEO Lee Jin-suk, participated in the 2024 Congress of the Société Internationale d’Urologie (SIU 2024) in New Delhi, India, from Oct. 23 to 26.
Huons Meditech participated in ICAP 2024 held in Jakarta, Indonesia, and is conducted promotional activities by detailing its products to attendees. [HUONS GLOBAL]

Huons Meditech, under the leadership of CEO Lee Jin-suk, participated in the 2024 Congress of the Société Internationale d’Urologie (SIU 2024) in New Delhi, India, from Oct. 23 to 26.

Through this event, the company aimed to demonstrate its advanced technology and strengthen its competitive presence on the global stage.

SIU, established in 1907, is one of the most distinguished international platforms focused on urological diseases and treatments, drawing thousands of experts from more than 100 countries each year. Attendees engage in sessions and exhibitions discussing the latest technological advancements and treatment methods shaping global urology.

At SIU 2024, Huons Meditech showcased its URO-UEMXD, an extracorporeal shock wave lithotripter (ESWL) that combines a shock wave head with an inline ultrasound probe, setting it apart from traditional X-ray-based devices. This approach enables both diagnosis and treatment of opaque and non-opaque urinary stones through ultrasound, allowing for heightened precision and minimizing reliance on X-ray imaging. The URO-UEMXD, developed in collaboration with India’s Vasu Group, was well-received at the event, underscoring Huons Meditech’s intention to capture a substantial portion of the global urology market.

Further enhancing the company’s impact, Prof. Yoon Hana, Korea’s first female urologist, presented on “The Current Trend of ESWL in Urolithiasis.” Her discussion emphasized the URO-UEMXD’s clinical efficacy and safety, supporting these claims with research findings that highlighted improved treatment outcomes and patient comfort.

In addition to SIU 2024, Huons Meditech participated in the International Congress of ASLS & Perdaweri Banten (ICAP 2024) in Jakarta, Indonesia. There, the focus shifted to strengthening the company’s influence in the global beauty device market, underscoring Huons Meditech’s diverse portfolio and international ambitions.

CEO Lee said that participating in these prominent international conferences has provided Huons Meditech with valuable exposure and networking opportunities, furthering the company’s reach in both the Indian and Indonesian markets. Emphasizing collaboration with global partners, he expressed the company’s commitment to actively expand its market share through strategic partnerships and continued innovation.

BY KIM YEONSOO [kim.yeonsoo1@joongang.co.kr]

Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.

이 기사에 대해 어떻게 생각하시나요?